Gens Krista D, Elshaboury Ramy H, Holt Jessica S
Department of Pharmacy, North Memorial Medical Center, Robbinsdale, MN, USA.
J Pharm Pract. 2013 Oct;26(5):498-505. doi: 10.1177/0897190013499527. Epub 2013 Aug 21.
Due to the increased incidence and recurrence of Clostridium difficile infection, health care providers are seeking new and alternative treatments to the standard antibiotic therapy. The objective of this article is to present a review on the background, microbiologic efficacy, clinical efficacy, and safety of fecal microbiota transplantation and to provide an overview of emerging treatment options currently under investigation. Emerging treatment options discussed include the use of monoclonal antibodies directed against toxins A and B, C difficile vaccination, and transplantation of nontoxigenic C difficile strains.
由于艰难梭菌感染的发病率和复发率不断上升，医疗保健提供者正在寻求标准抗生素治疗之外的新的替代治疗方法。本文的目的是对粪便微生物群移植的背景、微生物学疗效、临床疗效和安全性进行综述，并概述目前正在研究的新兴治疗选择。讨论的新兴治疗选择包括使用针对毒素A和B的单克隆抗体、艰难梭菌疫苗接种以及非产毒艰难梭菌菌株的移植。
